|
Dr. Lippa joined Aurora in September 2005. Dr. Lippa was co-founder of DOV Pharmaceutical, Inc.(Nasdq: DOVP), where he served as Chairman of the Board and Chief Executive Officer from its inception in April 1995. He stepped down as Chief Executive Officer in July of 2005 and continues to serve as Chairman. Prior to founding DOV in 1995, he founded Fusion Associates, Ltd., an investment and management company specializing in the creation and management of biomedical companies. In 1991, Fusion Associates founded and managed Hearing Innovations, Incorporated, a biomedical device company specializing in products for the hearing impaired. In 1990, Fusion founded and managed ChemWares, Inc., a diagnostic reagent company selling products for newborn screening. In 1989, Fusion Associates formed a limited partnership through which it acquired control of Vega Biotechnologies, Inc., a publicly held biotechnology company. Fusion Associates reorganized the financially troubled company and sold a majority position in 1992. In 1984, Arnold co-founded Praxis Pharmaceuticals, Inc. and took it public in 1985. He served as President and Chief Operating Officer from 1984 until 1987. Prior to 1985, he served as Director of Molecular Neurobiology and held other positions at the Medical Research Division of the American Cyanamid Corporation. Arnold has consulted for various pharmaceutical and biotechnology companies and was a graduate faculty professor at the New York University School of Medicine and the City University of New York. Dr. Lippa has held numerous scientific and editorial positions, has testified on the development of anti-AIDS drugs before a Congressional committee and has served as a consultant and special reviewer for the National Institutes of Health and the National Science Foundation. In 2004, Arnold was a founder and currently is a manager, and indirectly, a member of Atypical BioCapital Management LLC (Atypical Bio(tm)) and Atypical BioVentures Fund LLC, a life science fund management company and venture fund respectively. Atypical Bio(tm) also manages a micro cap and small cap public life science portfolio for a group of hedge funds. The Atypical Bio(tm) group is an affiliate of Aurora. | 